申请人:ONO PHARMACEUTICAL CO., LTD.
公开号:EP0757037A2
公开(公告)日:1997-02-05
The present invention relates to:
(i) matrix metalloproteinase (MMP) inhibitors containing sulfonylamino acid derivatives of the formula (Ia):
wherein R1 is hydrogen, C1-4 alkyl; R2 is hydrogen, C1-8 alkyl etc.; E is -CONR3-, in which R3 is hydrogen, C1-4 alkyl etc., -NR3CO-, -CO-O-, -O-CO- etc.; A is hydrogen, C1-8 alkyl, C3-7 cycloalkyl, or Ar; J is bond, C2-4 alkylene etc.; G is -(CH2)m-, in which m is 2, 3 or 4, or
in which R6 and R7 is hydrogen, C1-8 alkyl etc.; and non-toxic salts thereof,
(ii) novel sulfonylamino acid derivatives of the formula (Ib):
wherein all the symbols are as defined for formula (Ia), with the exclusion of certain compounds; and non-toxic salts thereof, and
(iii) processes for the preparation of the compounds of formula (Ib).
The compounds of formulae (Ia) and (Ib) are useful for prevention and/or treatment of diseases induced by overexpression or excess activity of MMP, such as rheumatoid diseases, arthrosteitis, unusual bone resorption, osteoporosis, periodontitis, interstitial nephritis, arteriosclerosis, pulmonary emphysema, cirrhosis, cornea injury, metastasis, invasion or growth of tumor cells, autoimmune diseases (Crohn's disease, Sjogren's syndrome etc.), diseases caused by vascular emigration or infiltration of leukocytes, or arterialization.
本发明涉及
(i) 含式(Ia)的磺酰基氨基酸衍生物的基质金属蛋白酶(MMP)抑制剂:
其中R1是氢、C1-4烷基;R2是氢、C1-8烷基等;E是-CONR3-,其中R3是氢、C1-4烷基等、-NR3CO-、-CO-O-、-O-CO-等;A是氢、C1-8烷基、C3-7环烷基或Ar;J是键、C2-4亚烷基等;G是-(CH2)m-,其中m是2、3或4,或
其中 R6 和 R7 是氢、C1-8 烷基等;以及它们的无毒盐、
(ii) 式(Ib)的新型磺酰基氨基酸衍生物:
其中所有符号与式 (Ia) 所定义的相同,但某些化合物除外;及其无毒盐,以及
(iii) 式(Ib)化合物的制备工艺。
式(Ia)和(Ib)化合物可用于预防和/或治疗因 MMP 过度表达或活性过强而诱发的疾病,如类风湿病、关节炎、异常骨吸收、骨质疏松症、牙周炎、间质性肾炎、动脉硬化、肺气肿、肝硬化、角膜损伤、肿瘤细胞转移、侵袭或生长、自身免疫性疾病(克罗恩病、Sjogren 综合征等)、血管外流引起的疾病。白细胞的血管迁移或浸润或动脉化引起的疾病。